search
Eli Lilly
Trends
- 1Eli Lilly CEO Touts Retatrutide As Next Growth Driver▼Eli Lilly CEO Bets On Weight-Loss Medicine Retatrutide As Next Growth Driver, Says Firm’s Future Has ‘Never Been Brighter’
Eli Lilly's chief executive said the company's future has 'never been brighter' as it bets on retatrutide, its experimental obesity and weight-loss drug, to become the next major growth driver. The remark signals confidence that Lilly will extend its lead in the booming weight-loss medicine market alongside its existing blockbuster drugs, keeping investors focused on the drug's development and approval prospects.
- 2Lilly launches pledge to close diabetes and obesity treatment gaps●Lilly launches the Lilly Change the Course Commitment, aiming to address treatment gaps in diabetes and obesity in LMICs
Eli Lilly has announced the Lilly Change the Course Commitment, a new initiative aimed at narrowing treatment gaps in diabetes and obesity care in low- and middle-income countries. The pharmaceutical company says the programme will focus on expanding access to treatment where need is greatest. Details on funding and specific country plans have not yet been widely reported.
- 3Jury Orders Eli Lilly to Pay Nektar $90 Million▼A Jury Awarded Nektar $90 Million From Eli Lilly. Here’s Why the Stock Barely Moved
A jury awarded Nektar Therapeutics $90 million in damages from Eli Lilly, yet Nektar's stock barely moved after the decision. Commentators attribute the muted reaction to the award being small relative to the stakes and uncertainty over whether the verdict will survive appeals. Investors appear to have largely priced in the outcome, with attention staying on Nektar's drug pipeline rather than litigation.